Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

23.86 +0.11 (+0.46%)
Streaming Delayed Price Updated: 9:47 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascentage Pharma Group International - American Depository Shares

News headline image
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 20, 2025 ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns' ↗
U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed. 
Via Benzinga
Topics Artificial Intelligence Government
News headline image
Penguin Solutions, Merit Medical Systems And 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? ↗
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan ↗
JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment. 
Via Benzinga
News headline image
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
IPO Momentum Builds In 2025: Diginex, CTRL Group, And Others Post Strong Gains ↗
US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more growth as 36 IPOs have already been priced this year, including Diginex's 600%... 
Via Benzinga
Topics Initial Public Offering
News headline image
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.